AnaptysBio, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026A legal dispute over a drug deal could affect company value and future partnerships.
The company is renting out office space to reduce costs while staying obligated to landlord.
Shareholders receive stock in a new independent company, affecting their ownership and taxes.
The company will report earnings on a new schedule, affecting when investors see financial results.
Quarterly earnings show whether the company is making or losing money.
Investors need company performance data to understand if their investment is doing well.
New financial leader oversees company money and budgets; his experience affects investor confidence.
Stocky reads AnaptysBio, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
AnaptysBio, Inc.'s most recent tracked filing was a 8-K on 30 Jul 2026: Trial held in Tesaro collaboration breach lawsuit.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.